As per the news Pfizer have wrote an application to the Food and Drug Administration on Friday an appeal for emergency use authorization for its experimental Covid-19 vaccine.
Well results from Pfizer phase 2 the clinical trials have extracted a news that two shots given three weeks apart, appears to be 95% effective in preventing the symptoms of the covid-19.
BioNTech the German partner of the Pfizer are poised to have made 50 million doses to made available this year and 1.3 billion in 2021, as using facilities both in United States and Belgium.
“our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of Covid-19 globally,” as said by Dr. Albert Bourla, Pfizer chairman and CEO in a news press release.
As per the companies they have initiated the rolling submissions with the medical helps from Europe and the United Kingdom and that they intend to “submit applications to the other regulatory agencies around the cosmos in the coming time.”
As per the Pfizer they require a ultracold storage, and they must be stored at minus 94-degree Fahrenheit is cooler than the standard cooling system at the health care keepers have across the globe.
To combat the problem of deep cold storage system Pfizer have developed a supercool storage unit that is packed with dry ice, and as per the health and human services secretary Alex Azar it will be reviewed by a independent pack of scientist before granting Pfizer the authorization.
It is crystal clear that we need more than one vaccine to fight this harmful pandemic. So as per the news the drug Moderna is expected to file for an emergency use and authorization of vaccine in the upcoming weeks ahead.